| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2016PLoSO..1152465F |
| P356 | DOI | 10.1371/JOURNAL.PONE.0152465 |
| P932 | PMC publication ID | 4811586 |
| P698 | PubMed publication ID | 27023064 |
| P50 | author | Mario Salmona | Q57097456 |
| Daniela Fenoglio | Q72525985 | ||
| P2093 | author name string | L Moretta | |
| A L Furfaro | |||
| C Domenicotti | |||
| M A Pronzato | |||
| M Nitti | |||
| N Traverso | |||
| S Piras | |||
| U M Marinari | |||
| A De Luigi | |||
| P2860 | cites work | Cysteine-based regulation of the CUL3 adaptor protein Keap1 | Q24629359 |
| The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress | Q24648021 | ||
| Regulation of glutathione synthesis | Q24655260 | ||
| The proteasome and the degradation of oxidized proteins: part III-Redox regulation of the proteasomal system | Q38190556 | ||
| Chemotherapy-induced neuropathy: A comprehensive survey | Q38211936 | ||
| Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma | Q38868828 | ||
| The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense. | Q38992060 | ||
| Targeting biliverdin reductase overcomes multidrug resistance in leukemia HL60 cells | Q39063812 | ||
| Biliverdin reductase plays a crucial role in hypoxia-induced chemoresistance in human glioblastoma | Q39082675 | ||
| RXRα inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2. | Q39161771 | ||
| Involvement of the Nrf2-proteasome pathway in the endoplasmic reticulum stress response in pancreatic β-cells | Q39283277 | ||
| Resistance of neuroblastoma GI-ME-N cell line to glutathione depletion involves Nrf2 and heme oxygenase-1. | Q39432948 | ||
| A new fluorogenic peptide determines proteasome activity in single cells. | Q39649696 | ||
| Redox mechanisms involved in the selective activation of Nrf2-mediated resistance versus p53-dependent apoptosis in adenocarcinoma cells | Q39818731 | ||
| The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response | Q39882024 | ||
| Bortezomib as a therapeutic candidate for neuroblastoma. | Q39943386 | ||
| CO and bilirubin inhibit doxorubicin-induced cardiac cell death | Q39945835 | ||
| CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. | Q40084964 | ||
| Activation of nuclear factor (erythroid-2 like) factor 2 by toxic bile acids provokes adaptive defense responses to enhance cell survival at the emergence of oxidative stress | Q40088792 | ||
| Catalytic activity of the proteasome fine-tunes Brg1-mediated chromatin remodeling to regulate the expression of inflammatory genes | Q42035318 | ||
| Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection | Q46058228 | ||
| Supplementation with N-acetylcysteine and taurine failed to restore glutathione content in liver of streptozotocin-induced diabetics rats but protected from oxidative stress. | Q46515062 | ||
| Tissue specific increase of the catalytic subunits of the 26S proteasome by indirect antioxidant dithiolethione in mice: enhanced activity for degradation of abnormal protein | Q48158503 | ||
| Evidences that leptin up-regulates E-cadherin expression in breast cancer: effects on tumor growth and progression. | Q51757944 | ||
| Neuroprotective effects of levetiracetam target xCT in astrocytes in parkinsonian mice. | Q52147727 | ||
| Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications | Q60548914 | ||
| High-performance liquid chromatography of thiols and disulfides: dinitrophenol derivatives | Q69405611 | ||
| Catalytic and regulatory properties of the heavy subunit of rat kidney gamma-glutamylcysteine synthetase | Q72231174 | ||
| Induction of glutamate-cysteine ligase (gamma-glutamylcysteine synthetase) in the brains of adult female mice subchronically exposed to methylmercury | Q73262835 | ||
| Ratio of reduced to oxidized glutathione as indicator of oxidative stress status and DNA damage | Q77897969 | ||
| Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease | Q79422098 | ||
| Proteasome inhibitor drugs on the rise | Q79966748 | ||
| Impaired synthesis contributes to diabetes-induced decrease in liver glutathione | Q83464965 | ||
| The Nrf2/HO-1 Axis in Cancer Cell Growth and Chemoresistance | Q26772298 | ||
| Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells | Q28393380 | ||
| Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression | Q29615644 | ||
| Modulation of oxidative stress as an anticancer strategy | Q29615707 | ||
| Association of reactive oxygen species levels and radioresistance in cancer stem cells | Q29617812 | ||
| Frequency Modulated Translocational Oscillations of Nrf2 Mediate the Antioxidant Response Element Cytoprotective Transcriptional Response. | Q30663205 | ||
| The modifier subunit of Drosophila glutamate-cysteine ligase regulates catalytic activity by covalent and noncovalent interactions and influences glutathione homeostasis in vivo | Q30979915 | ||
| A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma | Q33363081 | ||
| Glutathione and its role in cellular functions | Q33777917 | ||
| Neuroblastoma: biological insights into a clinical enigma | Q34180699 | ||
| The proteasome as a target for cancer therapy. | Q34286144 | ||
| Development of the proteasome inhibitor Velcade (Bortezomib). | Q34327233 | ||
| A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies | Q34526102 | ||
| p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. | Q34578157 | ||
| HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib | Q35079245 | ||
| BRG1 interacts with Nrf2 to selectively mediate HO-1 induction in response to oxidative stress | Q35131372 | ||
| Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy | Q35674558 | ||
| Nrf2-dependent gene expressions: a molecular toxicological aspect | Q35810501 | ||
| Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives | Q35836881 | ||
| Regulation of heme oxygenase-1 gene transcription: recent advances and highlights from the International Conference (Uppsala, 2003) on Heme Oxygenase | Q35877613 | ||
| Nrf2-dependent induction of proteasome and Pa28αβ regulator are required for adaptation to oxidative stress | Q35880062 | ||
| Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens | Q35983931 | ||
| Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation | Q36038160 | ||
| Heme oxygenase-1 in tumors: is it a false friend? | Q36174178 | ||
| Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha | Q36288735 | ||
| The ubiquitin-proteasome pathway in cancer | Q36295120 | ||
| The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer. | Q36297903 | ||
| Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo | Q37242431 | ||
| Discovery of the negative regulator of Nrf2, Keap1: a historical overview | Q37743470 | ||
| Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy | Q37777534 | ||
| Role of glutathione in cancer pathophysiology and therapeutic interventions | Q38006493 | ||
| The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation | Q38065567 | ||
| Role of Glutathione in Cancer Progression and Chemoresistance | Q38114436 | ||
| The significance of ferritin in cancer: Anti-oxidation, inflammation and tumorigenesis | Q38124651 | ||
| Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. | Q38160623 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neuroblastoma | Q938205 |
| P304 | page(s) | e0152465 | |
| P577 | publication date | 2016-03-29 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Role of Nrf2, HO-1 and GSH in Neuroblastoma Cell Resistance to Bortezomib | |
| P478 | volume | 11 |
| Q88682262 | Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer |
| Q41309443 | Differentiation impairs Bach1 dependent HO-1 activation and increases sensitivity to oxidative stress in SH-SY5Y neuroblastoma cells |
| Q38790184 | Effect of Lipoic Acid on the Biochemical Mechanisms of Resistance to Bortezomib in SH-SY5Y Neuroblastoma Cells |
| Q39285687 | HO-1 Induction in Cancer Progression: A Matter of Cell Adaptation |
| Q89820050 | Heme Oxygenase Dependent Bilirubin Generation in Vascular Cells: A Role in Preventing Endothelial Dysfunction in Local Tissue Microenvironment? |
| Q89287854 | Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib |
| Q92945947 | Isoflavone ME-344 Disrupts Redox Homeostasis and Mitochondrial Function by Targeting Heme Oxygenase 1 |
| Q90294380 | Molecular Mechanisms of Epigallocatechin-3-Gallate for Prevention of Chronic Kidney Disease and Renal Fibrosis: Preclinical Evidence |
| Q89706191 | Non-competitive heme oxygenase-1 activity inhibitor reduces non-small cell lung cancer glutathione content and regulates cell proliferation |
| Q38694717 | Nrf2: a potential therapeutic target for naturally occurring anticancer drugs? |
| Q37606602 | Oxidative Stress, Nrf2, and Epigenetic Modification Contribute to Anticancer Drug Resistance |
| Q39117499 | Polyphenols delivery by polymeric materials: challenges in cancer treatment. |
| Q64056540 | Potential Applications of NRF2 Inhibitors in Cancer Therapy |
| Q89920945 | Potential Applications of NRF2 Modulators in Cancer Therapy |
| Q92744839 | Pro-apoptotic effect of haem oxygenase-1 in human colorectal carcinoma cells via endoplasmic reticular stress |
| Q37687457 | Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells |
| Q41628271 | Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway |
| Q60919530 | Xiaochaihutang Inhibits the Activation of Hepatic Stellate Cell Line T6 Through the Nrf2 Pathway |
| Q55370004 | microRNA-494 Favors HO-1 Expression in Neuroblastoma Cells Exposed to Oxidative Stress in a Bach1-Independent Way. |
Search more.